Endocrine Abstracts

JOINT2126

Introduction and Objectives: Abaloparatide is part of the arsenal of osteoforming drugs, marketed in Europe since May 2024 for postmenopausal women at very high risk of fractures. Abaloparatide has been shown to reduce the risk of vertebral and non-vertebral fractures. However, there is scarce evidence in real life about the patient profile receiving this treatment. Therefore, this work aims to evaluate the clinical and analytical profile of the patient who is receiving abaloparatide in our center.

Material and Methods: Descriptive observational study of the profile of patients who started treatment with Abalopratide in the Endocrinology Service of the HUCSC of Granada in 2024. The results were analyzed in the SSPS 25. 0 program. Analytical variables, bone mineral density (BMD) and TBS were measured.

Results: Twenty women with mean age at diagnosis of osteoporosis of 62. 5 years were included. 20 % family history of hip fracture. 65% had a fragility fracture before treatment, 60% of which were vertebral and 10% hip fractures, with a mean number of fractures of 1. 9 +-1. 7 SD. 100% of the sample presented a very high risk of fracture. 55% received previous osteoporotic treatment. The mean T-SCORE value for femoral neck and total spine was -2. 3 and - 2. 6 respectively. The mean TBS level in the spine was 1. 17 and the mean Tscore was -3. The mean BMD value in the total spine was 0. 94 with a mean Tscore of -2. 6. The mean value of Creatinine, Calcium, Vitamin D and Parathormone was 0. 66 mg/dl, 9. 3 mg/dl, 30. 5 ng/mL and 68. 2 pg/mL respectively. The mean value of the remodeling markers C-terminal Telopeptide collagen type I and Procollagen I, N-terminal propeptide was 0. 51 ng/mL and 80. 3 ng/mL.

Conclusion: The patients who started Abaloparatide complied with the indications for treatment since they presented a high risk of fracture with greater involvement of trabecular bone in addition to presenting calcium and parathyroid hormone levels in the normal range.